Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Health integration in national climate adaptation policies from 198 countries: a global policy analysis.
Journal: The Lancet. Planetary health
Published: December 19, 2025
Identification of targets of clinical FOXA1 mutants involved in EMT and immune suppression in prostate cancer.
Journal: Communications biology
Published: August 19, 2025
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.
Journal: Signal transduction and targeted therapy
Published: July 17, 2025
Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells.
Journal: Molecular cancer therapeutics
Published: August 19, 2024
Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade.
Journal: medRxiv : the preprint server for health sciences
Published: August 16, 2024
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer.
Journal: Nature communications
Published: August 18, 2023
SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 07, 2023
Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.
Journal: Cancer research communications
Published: May 08, 2023
(CAAC)Copper Catalysis Enables Regioselective Three-Component Carboboration of Terminal Alkynes.
Journal: ACS catalysis
Published: May 05, 2023
CTLA-4 antibody-drug conjugate reveals autologous destruction of B-lymphocytes associated with regulatory T cell impairment.
Journal: bioRxiv : the preprint server for biology
Published: March 13, 2023
Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy.
Journal: Science translational medicine
Published: March 01, 2023
Last Updated: 09/26/2026